Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2026)
Coherus Oncology (CHRS) posted Other Operating Expenses of $3.8 million for Q1 2026, down 5.71% sequentially from $4.0 million in Q4 2025, and up 43.76% YoY from $2.7 million in Q1 2025.
Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2026) Analysis & Trends
Coherus Oncology has reported Other Operating Expenses for 8 years, with the latest figure at $3.8 million in Q1 2026.
- Quarterly Other Operating Expenses rose 43.76% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (up 50.64% YoY) and the FY2025 annual result came in at $13.8 million, up 58.29% from the prior year.
- Other Operating Expenses declined to $3.8 million in Q1 2026 per CHRS's latest filing, from $4.0 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $84.6 million in Q4 2023 and troughed at $1.4 million in Q1 2024.
- A 5-year average of $15.0 million and a median of $4.0 million in 2025 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Operating Expenses jumped 495.46% in 2023, then sank 96.75% in 2024.
- Over 5 years, Other Operating Expenses stood at $14.2 million in 2022, then surged by 495.46% to $84.6 million in 2023, then tumbled by 96.75% to $2.8 million in 2024, then soared by 47.09% to $4.0 million in 2025, then retreated by 5.71% to $3.8 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $3.8 million, $4.0 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.24 Mn |
| Mar 31, 2026 | 3.81 Mn |
| Dec 31, 2025 | 4.05 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 2.65 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 84.57 Mn |
| Sep 30, 2023 | 32.70 Mn |
| Jun 30, 2023 | 24.85 Mn |
| Mar 31, 2023 | 16.87 Mn |
| Dec 31, 2022 | 14.20 Mn |
| Sep 30, 2022 | 35.23 Mn |
| Jun 30, 2022 | 11.28 Mn |
| Mar 31, 2022 | 9.37 Mn |
| Dec 31, 2021 | 12.10 Mn |
| Sep 30, 2021 | 21.28 Mn |